Company: ABUS
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012305
Chunk: 42

Company: Arbutus Biopharma Corp
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 42
---
 received $17,250 of 401(k) matching contributions. In January 2025, Mr. McElhaugh’s annual base salary was increased to $530,450. Mr. McElhaugh’s employment as our Interim Chief Executive Officer was terminated effective February 24, 2025. David C. Hastings, Former Chief Financial Officer For fiscal 2024, Mr. Hasting’s annual base salary was $502,000 and his annual incentive cash target was 40% of his annual salary. In February 2025, Mr. Hastings received an annual incentive cash award of $200,800, which was equal to 40% of his annual salary for 2024, based on fiscal 2024 performance. In February 2024, Mr. Hastings received a stock option award exercisable for 450,000 shares with an aggregate grant date fair value of $837,524. The option vests based on continued employment or service and becomes exercisable 1/48 theach month over the four-year vesting period, has an exercise price of $2.40 and expires ten years from the grant date. In addition, Mr. Hastings received a grant for 112,500 restricted stock units with an aggregate grant date fair value of $270,000, which vest (or remain eligible to vest) based on continued employment or service over a three-year period in three equal annual installments beginning one year from the grant date. In 2024, Mr. Hastings also received $17,250 of 401(k) matching contributions. In January 2025, Mr. Hasting’s annual base salary was increased to $522,080. Mr. Hastings’s employment as our Chief Financial Officer was terminated effective as of the end of the day on March 27, 2025. Dr. Karen Sims, Former Chief Medical Officer For fiscal 2024, Dr. Sim’s annual base salary was $490,000 and her annual incentive cash target was 40% of her annual salary. In February 2025, Dr. Sims received an annual incentive cash award of $196,000, which was equal to 40% of her annual salary for 2024, based on fiscal 2024 performance. In February 2024, Dr. Sims received a stock option award exercisable for 403,900 shares with an aggregate grant date fair value of $751,725. The option vests based on continued employment or service and becomes exercisable 1/48 theach month over